One such target that was recently investigated in phase II and III trials was the heightened cardiac activity of ERK1/2, JNK, and p38 MAP kinases downstream from variants in LMNA associated with DCM (Muchir et al., 2012). The gene discussed is MAPK3; the disease is familial dilated cardiomyopathy.